Overactive bladder
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| ICD-10 | N32.8 |
|---|---|
| ICD-9 | 596.51 |
Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia." The International Continence Society(ICS) is responsible for this definition. There exists, however, some controversy over the use of this term because these symptoms taken in isolation may overlap with those of other bladder conditions, including interstitial cystitis, or rarely even bladder tumours.
The etiology of OAB is unclear, and indeed there may be multiple possible causes. It is often associated with detrusor overactivity, a pattern of bladder muscle contraction observed during urodynamics, and treatments for OAB, are usually synonymous with treatments for detrusor overactivity. OAB is distinct from stress urinary incontinence, but when they occur together is usually known as mixed incontinence.
Earlier reports estimated that about one in six adults in the United States or Europe had OAB.[1][1] Because the average age of people in the developed world is increasing, it is expected that OAB will become more common in the future as the prevalence of OAB increases with age.[1][1] However, a recent Finnish population-based survey[1] showed that the prevalence had been largely overestimated due to methodological shortcomings regarding age distribution and low participation (in earlier reports). OAB affects approximately half of that proposed earlier.[1]
Treatment for OAB includes lifestyle modification (fluid restriction, avoidance of caffeine), bladder retraining, antimuscarinic drugs (darifenacin, hyoscyamine, oxybutynin, tolterodine, solifenacin, trospium), and various devices (Urgent PC Neuromodulation System, InterStim). Intravesical botulinum toxin A is also used in some intractable cases, although not with formal FDA approval. The antimuscarinic fesoterodine was recommended for approval by the European Medicines Agency in February 2007, and will become available for use during 2008.
References
Support Resources
- Incontact.org
- The Continence Foundation
- Cystitis & Overactive Bladder Foundation - UK
- Canada IC & OAB Resource Center
Information Resources
- Overcoming Overactive Bladder
- Interstitial Cystitis Survival Guide
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
